Stalaris is a fusion protein commercialized by aTyr Pharma, with a leading Phase III program in Pulmonary Sarcoidosis. According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Stalaris’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Stalaris is expected to reach an annual total of $152 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
efzofitimod (ATYR-1923) is under development for the treatment of rare pulmonary diseases with an immune component (RPIC) including interstitial lung diseases such as chronic hypersensitivity pneumonitis and connective tissue diseases (CTD-ILD), pulmonary sarcoidosis and coronavirus disease 2019 (COVID-19) with severe pneumonia. It is administered by intravenous route. The drug candidate targets neuropilin-2. It is being developed based on tRNA synthetase platform. The drug candidate constitutes an immunoglobin Fc fused with the immuno-modulatory domain (iMod domain) of histidine aminoacyl tRNA synthetase (HARS).
aTyr Pharma Overview
aTyr Pharma is a clinical-stage biotechnology company. It is engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. Its ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to the neuropilin-2 receptor harnesses immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of extracellular functionality of tRNA synthetases. aTyr Pharma also develops drugs for cancer, inflammation, neurodegenerative diseases, and metabolic disorders. The company collaborates with research institutions for its research and development activities. aTyr Pharma is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$10.4 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$46.4 million in FY2022, compared to an operating loss of US$34 million in FY2021. The net loss of the company was US$45.3 million in FY2022, compared to a net loss of US$33.8 million in FY2021.
For a complete picture of Stalaris’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.